Publications by authors named "M Reck"
Introduction: RELAY, a global double-blind, placebo-controlled phase 3 study (NCT02411448) found statistically significant improvement in progression-free survival (primary end point) for ramucirumab (RAM) plus erlotinib (ERL) (RAM + ERL) in patients with untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59, 95% confidence interval [CI]: 0.46-0.
View Article and Find Full Text PDFWhat Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was in participants with small cell lung cancer (SCLC). Participants previously received at least two other treatments for their SCLC.
View Article and Find Full Text PDFArticle Synopsis
- The PERLA study compared the effectiveness and safety of two treatments—dostarlimab (DCT) and pembrolizumab (PCT)—alongside chemotherapy for patients with advanced non-small cell lung cancer.
- An exploratory analysis collected patient-reported outcomes (PROs) through various assessments over the treatment duration, with a focus on health-related quality of life.
- Results indicated that both treatments provided similar levels of quality of life, but DCT showed advantages in reducing dyspnea and chest pain, making it a viable option for future therapies.
Article Synopsis
- TTF-1 immunohistochemistry is commonly used to identify primary pulmonary adenocarcinomas, but it can also appear in various other cancer types.
- In a study involving 17,772 tumor samples, TTF-1 was found in 82 different tumor categories, indicating a broad range of malignancies where it may be present, spanning from thyroid cancers to neuroendocrine tumors.
- Although TTF-1 shows high sensitivity for distinguishing pulmonary adenocarcinomas, its specificity is low; combining TTF-1 with Napsin-A significantly enhances diagnostic accuracy.
Article Synopsis
- * A pooled analysis of clinical trials showed that patients receiving this combination treatment had better overall survival (17.4 months) compared to those receiving chemotherapy alone (11.3 months) at a median follow-up of 73.7 months.
- * The combination treatment also resulted in higher progression-free survival and objective response rates without new safety concerns, making it a promising first-line option for hard-to-treat NSCLC cases.